These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36099796)

  • 1. Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer.
    Johnson RP; Ratnacaram CK; Kumar L; Jose J
    Drug Resist Updat; 2022 Sep; 64():100865. PubMed ID: 36099796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted nanomedicine modalities for prostate cancer treatment.
    Cohen L; Livney YD; Assaraf YG
    Drug Resist Updat; 2021 May; 56():100762. PubMed ID: 33857756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Begemann D; Anastos H; Kyprianou N
    Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tea polyphenol-engineered hybrid cellular nanovesicles for cancer immunotherapy and androgen deprivation therapy.
    Guo Y; Wu J; Chen L; Liu L; Bi T; Pan Y; Meng QF; Wang C; Rao L; Li Q
    J Nanobiotechnology; 2024 Apr; 22(1):192. PubMed ID: 38637848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome.
    Malinen M; Niskanen EA; Kaikkonen MU; Palvimo JJ
    Nucleic Acids Res; 2017 Jan; 45(2):619-630. PubMed ID: 27672034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling Prostate Cancer Therapeutic Resistance.
    Wade CA; Kyprianou N
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.
    Nelson EC; Cambio AJ; Yang JC; Lara PN; Evans CP
    Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of androgen receptor targeted therapy for advanced prostate cancer.
    Wong YN; Ferraldeschi R; Attard G; de Bono J
    Nat Rev Clin Oncol; 2014 Jun; 11(6):365-76. PubMed ID: 24840076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The androgen receptor induces integrin α6β1 to promote prostate tumor cell survival via NF-κB and Bcl-xL Independently of PI3K signaling.
    Lamb LE; Zarif JC; Miranti CK
    Cancer Res; 2011 Apr; 71(7):2739-49. PubMed ID: 21310825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
    Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
    Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.
    Shore ND; Antonarakis ES; Cookson MS; Crawford ED; Morgans AK; Albala DM; Hafron J; Harris RG; Saltzstein D; Brown GA; Henderson J; Lowentritt B; Spier JM; Concepcion R
    Prostate; 2020 May; 80(6):527-544. PubMed ID: 32130741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor inhibits epithelial-mesenchymal transition, migration, and invasion of PC-3 prostate cancer cells.
    Huo C; Kao YH; Chuu CP
    Cancer Lett; 2015 Dec; 369(1):103-11. PubMed ID: 26297988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.
    Edlind MP; Hsieh AC
    Asian J Androl; 2014; 16(3):378-86. PubMed ID: 24759575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting androgen-independent pathways: new chances for patients with prostate cancer?
    Cattrini C; Zanardi E; Vallome G; Cavo A; Cerbone L; Di Meglio A; Fabbroni C; Latocca MM; Rizzo F; Messina C; Rubagotti A; Barboro P; Boccardo F
    Crit Rev Oncol Hematol; 2017 Oct; 118():42-53. PubMed ID: 28917268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent androgen deprivation therapy in advanced prostate cancer.
    Alva A; Hussain M
    Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway.
    Mellado B; Codony J; Ribal MJ; Visa L; Gascón P
    Clin Transl Oncol; 2009 Jan; 11(1):5-10. PubMed ID: 19155198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
    Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
    Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.